KalVista Pharmaceuticals KALV 深 沪
等待开盘 10-31 09:30:00 美东时间
10.92
-0.040
-0.36%
华盛通- 最 高11.30
- 今 开11.00
- 成交量 34.00万股
- 最 低 10.92
- 昨 收 10.96
- 总市值 5.52亿
- 52周最高 17.28
- 市盈率 静 --
- 换手率 0.67%
- 52周最低 7.30
- 委 比 1.76%
- 总股本 5052.33万
- 历史最高 45.00
- 量 比 0.35
- 振 幅 3.47%
- 历史最低 4.12
- 每 手 1
- 风险率 1.96%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多KalVista Pharmaceuticals Presents Data From KONFIDENT Studies On EKTERLY For Hereditary Angioedema, Highlights Need For Oral Alternatives To Injectable Therapies
Findings from KONFIDENT and KONFIDENT-S show rapid, effective treatment of HAE attacks among European participants; patient survey highlights barriers linked to injectable therapiesKalVista Pharmaceuticals, Inc.
10-07 04:03
KalVista Pharmaceuticals Announces New Executive Appointments
The latest announcement is out from KalVista Pharmaceuticals ( ($KALV) ). On Oc...
10-06 19:49
KalVista Pharmaceuticals Completes Convertible Notes Sale
The latest announcement is out from KalVista Pharmaceuticals ( ($KALV) ). On Se...
09-30 04:45
Ionis reports promising data from study of Alexander disease therapy
Ionis Pharmaceuticals (NASDAQ:IONS) has reported promising results from a pivotal study of its experimental medicine, zilganersen, for the treatment of Alexander disease, a rare and progressive neurol...
09-22 21:09
KalVista Pharma Says EC And Swissmedic Approve EKTERLY, Oral Plasma Kallikrein Inhibitor, For Symptomatic Treatment Of Acute Attacks Of HAE In Adults
First European launch of EKTERLY expected in Germany Q4 2025EKTERLY now approved in the US, EU, UK and Switzerland with additional regulatory applications under review in key global marketsKalVista Pharmaceuticals, Inc.
09-19 19:02
美股大行评级 | 潜在涨幅280.95%！HC Wainwright & Co.上调Immix Biopharma目标价至8美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Immix Biopharma"买入"评级，目标价从7美元升至8美元；Maxim Group：上调CNS Pharma评级至"买入"，目标价20美元
09-15 11:13
JMP Securities Maintains Market Outperform on KalVista Pharmaceuticals, Raises Price Target to $28
JMP Securities analyst Jonathan Wolleben maintains KalVista Pharmaceuticals (NASDAQ:KALV) with a Market Outperform and raises the price target from $27 to $28.
09-12 19:05
KalVista Pharmaceuticals Reports Strong Start for EKTERLY Launch
KalVista Pharmaceuticals, Inc. ( ($KALV) ) has released its Q1 earnings. Here i...
09-12 11:52
KalVista Pharmaceuticals GAAP EPS of -$1.12 misses by $0.17, revenue of $1.43M misses by $0.66M
KalVista Pharmaceuticals press release (NASDAQ:KALV): Q1 GAAP EPS of -$1.12 misses by $0.17. Revenue of $1.43M misses by $0.66M. As of July 31, 2025, the Company had cash, cash equivalents and marketa...
09-11 19:03
KalVista Pharma Q1 EPS $(1.12) Misses $(0.95) Estimate, Sales $1.426M Miss $2.089M Estimate
KalVista Pharma (NASDAQ:KALV) reported quarterly losses of $(1.12) per share which missed the analyst consensus estimate of $(0.95) by 17.28 percent. This is a 28.74 percent decrease over losses of $(0.87) per share from
09-11 19:01
